NEW YORK (GenomeWeb News) – Promise Advanced Proteomics, a French fee-for-service proteomics firm providing mass spectrometry-based absolute quantification services, has launched.
Based in Grenoble, France, Promise is a spinout of the Exploring the Dynamics of Proteomes laboratory at the National Institute of Health and Medical Research, the French Atomic Energy and Alternative Energies Commission, and Université Joseph Fourier. The company officially launched late last month, said Virginie Brun, the company's co-founder and chief scientific officer who was part of a team that developed the company's technology.
Promise provides services for the development of therapeutic proteins and biomarkers. Specifically, it employs a technology called Protein Standard Absolute Quantification for developing full-length isotopically-labeled proteins. The proteins can be used for quantitative proteomics and analytical research.
The technology was developed by researchers at the Exploring the Dynamics of Proteomes laboratory and was described in a 2007 interview with Brun by GenomeWeb Daily News' sister publication ProteoMonitor.
Promise holds an exclusive license to use the PSAQ technology, Brun said.
Nicolas Mouz is Promise's president and CEO.